BioSpace News Archive

Fervent Pharmaceuticals has announced the launch of clinical trials for their promising new post-menopausal drug therapy, FP-101.

-- Expands potential addressable patient population for H3 Biomedicine’s lead splicing modulator H3B-8800, currently in Phase 1 study for other hematologic malignancies -- -- Underscores promise of H3 Biomedicine’s product engine to identify previously unknown cancer drivers to inform discovery and development of next-generation targeted therapies --

CEO “extremely encouraged by the results from our ongoing Phase 1 trial of AB928.”

Company will showcase full suite of rehabilitation and pain management technologies in booth #1835

PierianDx, the leading genomics technology company that enables precision medicine, announced today a strategic partnership with RTI International to help solve the problem of translating complex genomic data into actionable clinical insight to advance precision medicine.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.

Designation based on Phase III HAVEN 3 study demonstrating HEMLIBRA prophylaxis significantly reduced bleeds compared to no prophylaxis

Projects include: investigating myelin repair strategies, the role of gut bacteria, and non-pharmaceutical approaches to managing debilitating pain in people with MS

More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program

Phase 2 Study of PTI-428 + Symdeko Planned to Initiate in 3Q'18.